49. Gauglianone P, Chan K, DelaFfor-Weiss E, Hanixh R, Jeffers S, Sharma D, Muggia F: Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994, 12:103–110.CrossRef find more 50. Eckardt JR, Campbell E, Burris HA, Weiss CR, Rodriguez CI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenbeig ML: A phase II trial of DaunoXome, liposome-encapsulated daunorubicin,
in patients with metastatic adenocarcinoma of the colon. Am Clin Oncol 1994, 17:498–501.CrossRef 51. Schurmann D, Dormann A, Grunewald T, Ruf B: Successful treatment of AIDS-related pulmonary Kaposi’s sarcoma with liposomal daunorubicin. Eur Respir J 1994, 7:824–825.CrossRef 52. New RRC, Chance SM, Thomas SC, Peters W: Nature antileishmanial activity of antimonials entrapped buy LY2835219 in liposomes. Nature 1978, 272:55–58.CrossRef 53. Lopez-Berestein G, Fainstein V, Hopter R, Mehta KR, Sullivan M, Keating M, Luna M, Hersh EM: Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer. J Infect Diseases 1985, 151:704–710.CrossRef 54. Lasic DD: Mixed micelles in drug delivery. Nature 1992, 355:279–280.CrossRef 55. Svenson CE, Popescu MC, Ginsberg RC: Liposome treatments of viral, bact and protozoal infections. Crit Rev Microbiol 1988, 15:S1-S31.CrossRef 56. Gabizon A: Liposomes as a drug delivery system in cancer therapy.
In Drug Carrier Systems. Edited by: Roerdink FHD, Kron AM. Chichester: Wiley; 1989:185–211. 57. Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJA: Influence of lipid composition on the antitumor activity exerted by doxorubicin containing liposomes in a rat solid tumor model. Cancer Res 1987, 47:3366–3372. 58. Akbarzadeh A, Asgari D, Zarghami N, Mohammad R, Davaran S: Preparation and in
vitro evaluation of doxorubicin-loaded Fe 3 O 4 magnetic nanoparticles modified with biocompatible co-polymers. Int J Nanomedicine 2012, 7:511–526. 59. Akbarzadeh A, Zarghami N, Mikaeili H, Asgari D, Goganian AM, Khiabani HK, very Samiei M, Davaran S: Synthesis, characterization, and in vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl 2012, 5:13–25. 60. Akbarzadeh A, Samiei M, Davaran S: Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett 2012, 7:144.CrossRef 61. Valizadeh A, Mikaeili H, Samiei M, Mussa Farkhani S, Zarghami N, Kouhi M, Akbarzadeh A, Davaran S: Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale Res Lett 2012, 7:480.CrossRef 62. Akbarzadeh A, Samiei M, Joo SW, Anzaby M, Hanifehpour Y, Nasrabadi HT, Davaran S: Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnology 2012, 10:46.CrossRef Competing interests The authors declare that they have no competing interests.